Status:
RECRUITING
ImmunoPET Imaging of Pancreatic Cancer
Lead Sponsor:
RenJi Hospital
Conditions:
Neoplasms Pancreatic
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Pancreatic cancer remains one of the most aggressive cancer types. Target-specific targeted therapy is an attractive therapeutic alternative for the treatment of patients with a wide range of cancers,...
Detailed Description
Enrolled patients with pancreatic cancer will undergo whole-body \[89Zr\]Zr-DFO-SHR1920 immunoPET/CT scans at 0,1, 3, 5, or 7 days after tracer injection (1-3 mCi). Uptake of \[89Zr\]Zr-DFO-SHR1920 in...
Eligibility Criteria
Inclusion
- Histologically confirmed diagnosis of pancreatic cancer or suspected pancreatic cancer by diagnostic imaging.
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Exclusion
- Known or suspected hypersensitivity to SHR1920, DFO/RESCA/NOTA, 89Zr/18F or 68Ga or any of the excipients.
- Pregnancy
Key Trial Info
Start Date :
November 20 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06602037
Start Date
November 20 2024
End Date
June 1 2027
Last Update
December 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, China, 200127